Ângela Sousa

Dr. Ângela Sousa

CICS-UBI Health Sciences Research Centre, University of Beira Interior, 6200–506 Covilhã, Portugal
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
AAAna M. Almeida
Ana M. Almeida
JQJoão A. Queiroz
João A. Queiroz
Fani SousaFani Sousa
Fani Sousa
Ângela SousaÂngela Sousa
Ângela Sousa

1 November 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
DEDalinda Eusébio
Dalinda Eusébio
ANAna R. Neves
Ana R. Neves
Diana Barata CostaDiana Barata Costa
Diana Barata Costa
SBSwati Biswas
Swati Biswas
Gilberto AlvesGilberto Alves
Gilberto Alves
Ângela SousaÂngela Sousa
Ângela Sousa

27 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ABAna Teresa Brinca
Ana Teresa Brinca
ARAna Cristina Ramalhinho
Ana Cristina Ramalhinho
Ângela SousaÂngela Sousa
Ângela Sousa
AOAntónio Hélio Oliani
António Hélio Oliani
LGLuiza Granadeiro
Luiza Granadeiro
Eugenia GallardoEugenia Gallardo
Eugenia Gallardo
Polycystic ovary syndrome (PCOS) represents one of the leading causes of anovulatory infertility and affects 5% to 20% of women worldwide. Until today, both the subsequent etiology and pathophysiology of PCOS remain unclear, and patients with PCOS that undergo assisted reproductive techniques (ART) might present a poor to exaggerated response, low oocyte quality, ovarian hyperstimulation syndrome, as well as changes in the follicular fluid metabolites pattern. These abnormalities originate a decrease of Metaphase II (MII) oocytes and decreased rates for fertilization, cleavage, implantation, blastocyst conversion, poor egg to follicle ratio, and increased miscarriages. Focus on obtaining high-quality embryos has been taken into more consideration over the years. Nowadays, the use of metabolomic analysis in the quantification of proteins and peptides in biological matrices might predict, with more accuracy, the success in assisted reproductive technology. In this article, we review the use of human follicular fluid as the matrix in metabolomic analysis for diagnostic and ART predictor of success for PCOS patients.

7 September 2012 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
Ângela SousaÂngela Sousa
Ângela Sousa
Fani SousaFani Sousa
Fani Sousa
JQJoão A. Queiroz
João A. Queiroz

1 December 2011 in Journal of Controlled Release
Verified
Journal Article
Closed access
Vítor GasparVítor Gaspar
Vítor Gaspar
ICIlídio Correia
Ilídio Correia
Ângela SousaÂngela Sousa
Ângela Sousa
FSFilomena Silva
Filomena Silva
Catarina PaqueteCatarina Paquete
Catarina Paquete
Fani SousaFani Sousa
Fani Sousa

2 May 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
Miguel FerreiraMiguel Ferreira
Miguel Ferreira
Diana Barata CostaDiana Barata Costa
Diana Barata Costa
Ângela SousaÂngela Sousa
Ângela Sousa
Cancer is the second leading cause of death worldwide. Cervical cancer, for instance, is considered a major scourge in low-income countries. Its development is mostly associated with the human papillomavirus persistent infection and despite the availability of preventive vaccines, they are only widely administered in more developed countries, thus leaving a large percentage of unvaccinated women highly susceptible to this type of cancer. Current treatments are based on invasive techniques, being far from effective. Therefore, the search for novel, advanced and personalized therapeutic approaches is imperative. Flavonoids belong to a group of natural polyphenolic compounds, well recognized for their great anticancer capacity, thus promising to be incorporated in cancer therapy protocols. However, their use is limited due to their low solubility, stability and bioavailability. To surpass these limitations, the encapsulation of flavonoids into delivery systems emerged as a valuable strategy to improve their stability and bioavailability. In this context, the aim of this review is to present the most reliable flavonoids-based delivery systems developed for anticancer therapies and the progress accomplished, with a special focus on cervical cancer therapy. The gathered information revealed the high therapeutic potential of flavonoids and highlights the relevance of delivery systems application, allowing a better understanding for future studies on effective cancer therapy.